GlassScriptPhysician profile
Gul E Rukh Ferdousi
NPI 1003267527
$2,478.73
in general payments reported to CMS, 2019-2025
23 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.42 · 2020: $254 · 2021: $360 · 2022: $350 · 2023: $446 · 2024: $385 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $313.13 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $237.84 | 2019-2025 | |
| Amgen INC. | $208.75 | 2020-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $161.17 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $143.90 | 2020-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.51 | 2022-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $100.96 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $89.47 | 2023-2025 | |
| Abbvie INC. | $85.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $84.41 | 2021-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $63.46 | 2023-2024 | Freestyle Libre 3 |
| Nalu Medical, INC. | $43.85 | 2025 | Nalu Neurostimulation System |
| Biohaven Pharmaceuticals, INC. | $40.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.45 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.22 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $35.80 | 2022 | |
| Currax Pharmaceuticals LLC | $28.24 | 2025 | Contrave, Onzetra Xsail |
| Medtronic, INC. | $24.68 | 2022 | |
| Mylan Specialty L.P. | $23.23 | 2023 | Yupelri |
| Astellas Pharma US INC | $22.52 | 2024 | Veozah |
| Dynavax Technologies Corporation | $21.69 | 2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $18.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gul E Rukh Ferdousi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.